Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Ca
Go back to Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Ca| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 56.87 -1.26 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.13 | 52 Week High | $77.12 | |||
| Open | $57.74 | 52 Week Low | $49.03 | |||
| Day High | $58.11 | P/E | 36.93 | |||
| Day Low | $56.49 | EPS | $1.54 | |||
| Volume | 4,955,986 | |||||
